A
AltPep
Develops early disease-modifying treatments and detection tools for amyloid diseases
About AltPep
AltPep is a privately-held biotech startup that operates in the healthcare sector, specifically focusing on the development of early disease-modifying treatments and detection tools for amyloid diseases such as Alzheimer's and Parkinson's. The company's primary objective is to identify these diseases long before symptoms occur and neutralize the toxic soluble oligomers associated with them.
AltPep's business model revolves around the development and commercialization of its proprietary platform based on a library of custom-designed synthetic peptides. This library is used to target one of the earliest molecular triggers of amyloid diseases. The company is also developing highly sensitive blood tests to aid in the early detection of these diseases.
The company recently raised $52.9 million in venture financing, indicating strong investor confidence in its innovative approach. The funds will be used to advance its novel therapeutics into the clinical stage, which is a critical step towards commercialization.
AltPep's clients are primarily healthcare providers and patients suffering from amyloid diseases. The company generates revenue through the development and sale of its diagnostic tools and therapeutic treatments.
In summary, AltPep is a promising biotech startup with a unique approach to tackling some of the most challenging diseases in healthcare. Its innovative platform and strong financial backing position it well for future growth in the biotech industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Seattle, United States
- Employees
- 33
- Open positions
- 3
- Dealroom signal
- 68.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Alzheimers Disease, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2023 | $53M | $212M | Partners Investment · Eli Lilly · Matrix Capital Management · Senator Investment Group | ↗ |
| SERIES AOther financing | Jan 2021 | $23M | $92M | Matrix Capital Management · Alexandria Venture Investments | — |
Growth signals
Latest recorded traffic for AltPep is 4.4K monthly website visits, up 22.2% over the last three months. AltPep's team declined 2.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Matrix Capital Management
Alexandria Venture Investments
Partners Investment
Eli Lilly
Senator Investment Group
Section 32
Other known investors1 additional known investor
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AltPep on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AltPep’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.